Cargando…
Treatment Outcomes of Graded Dose of Empagliflozin in Type-2 Diabetes: A Real World Study
BACKGROUND: Costs are important cause of therapeutic noncompliance in type-2 diabetes mellitus (T2DM). Half-tablet empagliflozin (EMPA)-25 mg has lowest monthly cost among all EMPA preparations; data is unavailable on efficacy of half EMPA-25. This study compared real world weight loss and glycaemic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020632/ https://www.ncbi.nlm.nih.gov/pubmed/35313401 http://dx.doi.org/10.4103/aam.aam_69_20 |